Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013;8(4):e58817.
doi: 10.1371/journal.pone.0058817. Epub 2013 Apr 3.

Serious treatment related adverse drug reactions amongst anti-retroviral naïve MDR-TB patients

Martha Van der Walt  1 , Johanna Lancaster, Ronel Odendaal, Jeanne Garcia Davis, Karen Shean, Jason Farley
Affiliations

Serious treatment related adverse drug reactions amongst anti-retroviral naïve MDR-TB patients

Martha Van der Walt et al. PLoS One. 2013.

Abstract

Background: Globally treatment outcomes for multidrug-resistant Mycobacterium tuberculosis (MDR-TB) remain poor and this is compounded by high drug toxicity. Little is known about the influence of adverse drug reactions (ADRs) on treatment outcomes in South Africa.

Methods: We evaluated the impact of severe ADRs among a prospective cohort of MDR-TB patients in South Africa (2000-2004). The HIV-infected study participants were anti-retroviral naïve.

Results: Of 2,079 patients enrolled, 1,390 (66.8%) were included in this analysis based on known HIV test results (39.1% HIV-infected). At least one severe ADR was reported in 83 (6.9%) patients with ototoxicity being the most frequent ADR experienced (38.9%).

Conclusions: We found that being HIV-infected but antiretroviral naïve did not increase occurrence of SADRs in patients on second-line anti-tuberculosis drugs. Early screening and proactive management of ADRs in this patient population is essential, especially given the rollout of decentralized care and the potential for overlapping toxicity of concomitant MDR-TB and HIV treatment.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Study plan stratified by HIV status.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, et al. (2009) Treatment outcomes among patients with multidrug-resistant tuberculosis: Systematic review and meta-analysis. Lancet Infect Dis 9: 153–161. - PubMed
    1. Sterling TR, Pham PA, Chaisson RE (2010) HIV infection-related tuberculosis: Clinical manifestations and treatment. Clin Infect Dis, Suppl 3: S223–S230. - PubMed
    1. Scano F, Vitoria M, Burman W, Harries AD, Gilks C F, et al. (2008) Management of HIV-infected patients with MDR- and XDR-TB in resource-limited settings. Int J Tuberc Lung Dis 12: 1370–1375. - PubMed
    1. World Health Organisation (2008) Guidelines for the programmatic management of drug- resistant tuberculosis: Emergency update 2008. World Health Organisation: Geneva.
    1. Shean KP, Willcox PA, Siwendu SN, Laerson KF, Gross L (2008) Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 1992-2002. Int J Tuberc Lung Dis 12: 1182–1189. - PubMed

Publication types

MeSH terms